[Effect of the oral beta-mimetic drug clenbuterol (Contraspasmin, Spiropent) and orally and intravenously administered Partusisten on the rheobase].
Clenbuterol (Contraspasmin, Spiropent) was used to treat threatened delivery in a dosage of three times 0.02 mg per day because of its beta-mimetic effects and the halflife time for elimination of 34 hours. We examined the effect of Clenbuterol on the maternal rheobase as a factor to estimate the influence of this drug on neuromuscular structures of maternal organism. After the first oral application of Clenbuterol we found a significant decrease in this value and after second and third application a distinct fluctuation. This fact shows besides the positive beta-mimetic properties the side-effects on the vegetative nerve system and on neuromuscular structures of the female body.
D000284:Administration, Oral; D002976:Clenbuterol / Q000008:administration & dosage / Q000494:pharmacology*; D004558:Electric Stimulation; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007263:Infusions, Parenteral; D009119:Muscle Contraction / Q000187:drug effects; D009469:Neuromuscular Junction / Q000187:drug effects*; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D013607:Tablets
D004983:Ethanolamines; D013607:Tablets; D005280:Fenoterol; D002976:Clenbuterol
Der Einfluss des oralen Betamimetikum Clenbuterol (Contraspasmin, Spiropent) sowie oral und intravenös verabfolgten Partusistens auf die Rheobase.